Literature DB >> 33649296

TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity.

Gang Yan1, Meiou Dai1, Chenjing Zhang1,2, Sophie Poulet1, Alaa Moamer1, Ni Wang1, Julien Boudreault1, Suhad Ali1, Jean-Jacques Lebrun3.   

Abstract

Basal-like triple-negative breast cancers (TNBCs) display poor prognosis, have a high risk of tumor recurrence, and exhibit high resistance to drug treatments. The TNBC aggressive features are largely due to the high proportion of cancer stem cells present within these tumors. In this study, we investigated the interplay and networking pathways occurring between TGFβ family ligands in regulating stemness in TNBCs. We found that TGFβ stimulation of TNBCs resulted in enhanced tumorsphere formation efficiency and an increased proportion of the highly tumorigenic CD44high/CD24low cancer stem cell population. Analysis of the TGFβ transcriptome in TNBC cells revealed bone morphogenetic protein4 (BMP4) as a main TGFβ-repressed target in these tumor cells. We further found that BMP4 opposed TGFβ effects on stemness and potently decreased cancer stem cell numbers, thereby acting as a differentiation factor in TNBC. At the molecular level, we found that TGFβ inhibition of BMP4 gene expression is mediated through the Smad pathway and cyclin D1. In addition, we also found BMP4 to act as a pro-differentiation factor in normal mammary epithelial cells and promote mammary acinar formation in 3D cell culture assays. Finally, and consistent with our in vitro results, in silico patient data analysis defined BMP4 as a potential valuable prognosis marker for TNBC patients.

Entities:  

Year:  2021        PMID: 33649296     DOI: 10.1038/s41389-021-00310-5

Source DB:  PubMed          Journal:  Oncogenesis        ISSN: 2157-9024            Impact factor:   7.485


  70 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Authors:  Dabei Tang; Shanqi Xu; Qingyuan Zhang; Wenhui Zhao
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

3.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

Authors:  Bruce G Haffty; Qifeng Yang; Michael Reiss; Thomas Kearney; Susan A Higgins; Joanne Weidhaas; Lyndsay Harris; Willam Hait; Deborah Toppmeyer
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

4.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

5.  Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.

Authors:  Jiehua He; Roujun Peng; Zhongyu Yuan; Shusen Wang; Jiewen Peng; Guinan Lin; Xiaomei Jiang; Tao Qin
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

Review 6.  Cancer Stem Cells: The Architects of the Tumor Ecosystem.

Authors:  Briana C Prager; Qi Xie; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2019-01-03       Impact factor: 24.633

7.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Authors:  Sherene Loi; Nicolas Sirtaine; Fanny Piette; Roberto Salgado; Giuseppe Viale; Françoise Van Eenoo; Ghizlane Rouas; Prudence Francis; John P A Crown; Erika Hitre; Evandro de Azambuja; Emmanuel Quinaux; Angelo Di Leo; Stefan Michiels; Martine J Piccart; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

8.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Carsten Denkert; Sibylle Loibl; Aurelia Noske; Marc Roller; Berit Maria Müller; Martina Komor; Jan Budczies; Silvia Darb-Esfahani; Ralf Kronenwett; Claus Hanusch; Christian von Törne; Wilko Weichert; Knut Engels; Christine Solbach; Iris Schrader; Manfred Dietel; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  A clinically relevant gene signature in triple negative and basal-like breast cancer.

Authors:  Achim Rody; Thomas Karn; Cornelia Liedtke; Lajos Pusztai; Eugen Ruckhaeberle; Lars Hanker; Regine Gaetje; Christine Solbach; Andre Ahr; Dirk Metzler; Marcus Schmidt; Volkmar Müller; Uwe Holtrich; Manfred Kaufmann
Journal:  Breast Cancer Res       Date:  2011-10-06       Impact factor: 6.466

Review 10.  Cancer stem cells as key drivers of tumour progression.

Authors:  Ain Zubaidah Ayob; Thamil Selvee Ramasamy
Journal:  J Biomed Sci       Date:  2018-03-06       Impact factor: 8.410

View more
  4 in total

Review 1.  Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.

Authors:  Shogo Ehata; Kohei Miyazono
Journal:  Front Cell Dev Biol       Date:  2022-05-25

2.  Generation and functional characterization of murine mammary organoids.

Authors:  Hon Yan Kelvin Yip; Antonella Papa
Journal:  STAR Protoc       Date:  2021-08-24

Review 3.  Targeting Breast Cancer and Their Stem Cell Population through AMPK Activation: Novel Insights.

Authors:  Bhawna Uprety; Heidi Abrahamse
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

4.  High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer.

Authors:  Abdul K Siraj; Sandeep Kumar Parvathareddy; Padmanaban Annaiyappanaidu; Saeeda O Ahmed; Nabil Siraj; Asma Tulbah; Fouad Al-Dayel; Dahish Ajarim; Khawla S Al-Kuraya
Journal:  Onco Targets Ther       Date:  2021-05-19       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.